Marc Wehrli

1.3k total citations
24 papers, 830 citations indexed

About

Marc Wehrli is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Marc Wehrli has authored 24 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Marc Wehrli's work include CAR-T cell therapy research (13 papers), Virus-based gene therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). Marc Wehrli is often cited by papers focused on CAR-T cell therapy research (13 papers), Virus-based gene therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). Marc Wehrli collaborates with scholars based in United States, Switzerland and Netherlands. Marc Wehrli's co-authors include Marcela V. Maus, Stephan von Gunten, Hans‐Uwe Simon, Christoph Schneider, Camilla Jandus, Gabriela M. Baerlocher, Kayluz Frias Boligan, Meike Dahlhaus, He Liu and Thomas Démoulins and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Marc Wehrli

23 papers receiving 820 citations

Peers

Countries citing papers authored by Marc Wehrli

Since Specialization

Citations

This map shows the geographic impact of Marc Wehrli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Wehrli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Wehrli more than expected).

Fields of papers citing papers by Marc Wehrli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Wehrli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Wehrli. The network helps show where Marc Wehrli may publish in the future.

Co-authorship network of co-authors of Marc Wehrli

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Wehrli. A scholar is included among the top collaborators of Marc Wehrli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Wehrli. Marc Wehrli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy 2025 ·Hematological Oncology ·Jonas S. Jutzi, Jason A. Wampfler, (unknown), (unknown), (unknown), Michèle J. Hoffmann, (unknown), (unknown), (unknown), (unknown), Bernhard Lüscher, Ulrike Bacher, Marc Wehrli, Michael Daskalakis, Thomas Pabst, Urban Novak	0
2	Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics 2024 ·Science Translational Medicine ·Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Amanda A. Bouffard, Harrison Silva, (unknown), Trisha R. Berger, Michael C. Kann, (unknown), (unknown), Marc Wehrli, Nicholas J. Haradhvala, Stefanie R. Bailey, Anthony Letai, Marcela V. Maus	14
3	CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML 2024 ·Blood ·Harrison Silva, (unknown), (unknown), Marc Wehrli, Michael C. Kann, (unknown), (unknown), Charlotte Graham, (unknown), Amanda A. Bouffard, (unknown), Giulia Escobar, (unknown), (unknown), (unknown), Trisha R. Berger, Bryan D. Choi, Marcela V. Maus, Mark B. Leick	11
4	Abstract 4098: Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics 2023 ·Cancer Research ·Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Harrison Silva, (unknown), Trisha R. Berger, Amanda A. Bouffard, Michael C. Kann, (unknown), (unknown), Marc Wehrli, Stefanie R. Bailey, (unknown), Marcela V. Maus	3
5	“Hurdles race for CAR T‐cell therapy in digestive tract cancer” 2023 ·Immunological Reviews ·(unknown), Marc Wehrli, Diego Salas‐Benito, Marcela V. Maus	10
6	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia 2022 ·Cancer Cell ·Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca C. Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Nora Horick, Matthew J. Frigault, Marcela V. Maus	88
7	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME) 2022 ·Cancer Research ·Marc Wehrli, (unknown), Rebecca Larson, Irene Scarfò, Amanda A. Bouffard, Korneel Grauwet, Mark B. Leick, Andrea Schmidts, Stefanie R. Bailey, (unknown), Michael Kann, (unknown), (unknown), Kathleen Gallagher, Max Jan, Bryan D. Choi, (unknown), Marcela V. Maus	1
8	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) 2022 ·Journal for ImmunoTherapy of Cancer ·Marc Wehrli, Kathleen Gallagher, Yi‐Bin Chen, Mark B. Leick, Steven L. McAfee, Areej El‐Jawahri, Zachariah DeFilipp, Nora Horick, Paul V. O’Donnell, Thomas R. Spitzer, (unknown), Daniella Cook, (unknown), (unknown), Marcela V. Maus, Matthew J. Frigault	80
9	Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity 2021 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Steven M. Offer, Didier Meulendijks, Christos T. Nakas, Robert B. Diasio, Stefano Fontana, Marc Wehrli, Stefan Schürch, Ursula Amstutz, Carlo R. Largiadèr	23
10	New CARs on and off the road: challenges and new developments in CAR-T cell therapy 2021 ·Current Opinion in Pharmacology ·Marc Wehrli, Marcela V. Maus	3
11	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia 2021 ·Blood ·Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca C. Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Matthew J. Frigault, Marcela V. Maus	4
12	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies 2021 ·Blood ·Matthew J. Frigault, Yi‐Bin Chen, Kathleen Gallagher, Nora Horick, Areej El‐Jawahri, Irene Scarfò, Marc Wehrli, Lu Huang, Keagan S. Casey, Daniella Cook, Thomas R. Spitzer, Steven L. McAfee, Frederic I. Preffer, Myriam Armant, Kit L. Shaw, Heather Daley, Sarah Nikiforow, Jerome Ritz, Marcela V. Maus	11
13	Isolation of Antibodies from Human Plasma, Saliva, Breast Milk, and Gastrointestinal Fluid 2017 ·Methods in molecular biology ·Christoph Schneider, (unknown), Marius Lötscher, Marc Wehrli, Stephan von Gunten	7
14	Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement 2017 ·The Oncologist ·Marc Wehrli, Elisabeth Oppliger Leibundgut, (unknown), Markus G. Manz, Antonia Müller, Jeroen S. Goede	9
15	Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance 2014 ·Journal of Clinical Investigation ·Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E. Hunger, Gabriela M. Baerlocher, Hans‐Uwe Simon, Pedro Romero, Christian Münz, Stephan von Gunten	334
16	Human IgA Fc Receptor FcαRI (CD89) Triggers Different Forms of Neutrophil Death Depending on the Inflammatory Microenvironment 2014 ·The Journal of Immunology ·Marc Wehrli, (unknown), Ruslan Hlushchuk, Fritz Daudel, Peter M. Villiger, Sylvia Miescher, Adrian W. Zuercher, Valentin Djonov, Hans‐Uwe Simon, Stephan von Gunten	28
17	Cell Death in Immune Thrombocytopenia: Novel Insights and Perspectives 2013 ·Seminars in Hematology ·Stephan von Gunten, Marc Wehrli, Hans‐Uwe Simon	11
18	Macrophages and dendritic cells express tight junction proteins and exchange particles in an in vitro model of the human airway wall 2010 ·Immunobiology ·Fabian Blank, Marc Wehrli, Andrea Lehmann, Oliver Baum, Peter Gehr, Christophe von Garnier, Barbara Rothen‐Rutishauser	63
19	The epithelial integrity is preserved during particle exchange across the epithelium by macrophages and dendritic cells 2008 ·European Respiratory Review ·Fabian Blank, Marc Wehrli, Oliver Baum, Peter Gehr, Barbara Rothen‐Rutishauser	2
20	Diagnosis of a cholangiocarcinoma in an Arabian stallion 2005 ·Pferdeheilkunde Equine Medicine ·(unknown), Nicole Borel, Stefanie Ohlerth, Marc Wehrli, Karsten Feige	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact